Treakisym Blood Cancer Drug Information

• January 6, 2016
• Reading time: 1 minute

Based on a December 24, 2015 press release from SymBio Pharmaceuticals, the manufacturer of Treakisym (bendamustine) — a drug for lymphoma — the company has submitted a regulatory application in Japan for Treakisym in blood cancers including chronic lymphocytic leukemia (CLL). Prior clinical trials enrolled patients with refractory intermediate- or high-grade non-Hodgkin lymphoma and previously untreated multiple myeloma patients.

Key Points from the Press Releases

1. Application for approval of TREAKISYM for chronic lymphocytic leukemia (CLL)
2. Application for first-line treatment use in low-grade non-Hodgkin lymphoma and mantle cell lymphoma
3. For rare cancers, the company seeks to shorten the regulatory review period in Japan

Sources:

• http://www.symbiopharma.com/news/20151224_03.pdf
• http://www.symbiopharma.com/news/20151224_02.pdf
• http://www.symbiopharma.com/news/20151224_01.pdf

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4